AusBiotech Invest 2025

Following AusBiotech Invest 2025 on Tuesday as part of the AusBiotech International Conference 2025, Stockhead captured some of the key themes shaping the future of life sciences investment. Thank you to Steve Burnell , Dr Bianca Ogden and Sarah Meibusch for sharing their perspectives on how Australia can strengthen its capital stack and support companies to scale locally. And thank you to Nadine McGrath and the Stockhead team for the insightful coverage. 🔗 Read the full article: https://lnkd.in/gTU-4Wzm #LifeSciences #Biotech #Investment #Innovation

Today, Melbourne comes alive as the heart of Australia’s life sciences ecosystem. 23 pioneering biotech ventures are stepping onto the stage to showcase their breakthroughs to a curated audience of global investors, industry leaders, and strategic partners. From cutting-edge research to transformative technologies, these companies are poised to shape the future of the biotechnology industry. As the day continues to unfold, expect high-impact pitch sessions, expert-led panels, and invaluable opportunities. Whether you're here to discover the next big thing or to connect with visionary founders, AusBiotech Invest is where capital meets innovation. Let’s make today a milestone in advancing Australia's biotech ecosystem. #AusBiotechInvest2025 #ABI25 #BiotechInnovation #InvestmentOpportunities #LifeSciences

𝐀𝐮𝐬𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐈𝐧𝐯𝐞𝐬𝐭 2025 𝐢𝐬 𝐥𝐢𝐯𝐞! Over 20 of the leading biotech innovators from across Australia are pitching to a room of leading investors in Melbourne today, as together they look to redefine the future of biotech in Australia. #ausbiotech #ausbiotechinvest #ausbiotech2025 #invest #innovation #lifesciences

𝐖𝐞 𝐚𝐫𝐞 𝐣𝐮𝐬𝐭 𝐡𝐨𝐮𝐫𝐬 𝐚𝐰𝐚𝐲 𝐟𝐫𝐨𝐦 𝐀𝐮𝐬𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐈𝐧𝐯𝐞𝐬𝐭 2025 𝐛𝐞𝐠𝐢𝐧𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐰𝐞 𝐜𝐨𝐮𝐥𝐝𝐧'𝐭 𝐛𝐞 𝐦𝐨𝐫𝐞 𝐞𝐱𝐜𝐢𝐭𝐞𝐝. 𝐓𝐚𝐤𝐢𝐧𝐠 𝐩𝐥𝐚𝐜𝐞 𝐚𝐭 𝐂𝐫𝐨𝐰𝐧 𝐓𝐨𝐰𝐞𝐫𝐬, 𝐌𝐞𝐥𝐛𝐨𝐮𝐫𝐧𝐞 𝐨𝐧 21 𝐎𝐜𝐭𝐨𝐛𝐞𝐫 2025, this event will kick start the biggest week in biotech. AusBiotech Invest 2025 is the catalyst for the partnerships that will accelerate discovery and the investments that will save lives. Head of Investment Kerri Lee Sinclair and the rest of the team can't wait to see you there. More information including information about all the biotech brands who will be pitching can be found on the website https://lnkd.in/gkyvu6ZD #AusBiotechInvest #BiotechInvestment #HealthTech #Innovation #Networking #VentureCapital #DrugDevelopment #LifeScienceAustralia #AusBiotech

𝐇𝐞𝐚𝐫 𝐟𝐫𝐨𝐦 𝐚 𝐠𝐥𝐨𝐛𝐚𝐥 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐥𝐞𝐚𝐝𝐞𝐫 𝐨𝐧 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 - 𝐨𝐧𝐥𝐲 𝐚𝐭 𝐀𝐮𝐬𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐈𝐧𝐯𝐞𝐬𝐭 2025. We’re thrilled to welcome Gerry Brunk, Co-Founder and Managing Director of Lumira Ventures, as a keynote speaker at AusBiotech Invest 2025. Based in Boston, Gerry has led investments in over 30 groundbreaking biotech and medical device companies, including HistoSonics, Inc., MAKO Surgical Corp., Pharmasset, Inc., Endotronix, and more. With over $700M under management and a career spanning entrepreneurship, venture investing, and strategic healthcare advisory, Gerry brings unmatched insight into the future of healthcare innovation. 21 October 2025 Crown Towers, Melbourne Make sure you're in the room by registering now https://lnkd.in/gsbdEJbB #AusBiotechInvest2025 #ABI25 #LifeSciences #BiotechInvestment #CapitalStack #Innovation #HealthTech #AusBiotech

𝐀𝐮𝐬𝐭𝐫𝐚𝐥𝐢𝐚 𝐡𝐚𝐬 𝐭𝐡𝐞 𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐛𝐮𝐭 𝐧𝐨𝐭 𝐭𝐡𝐞 𝐬𝐜𝐚𝐥𝐞—𝐢𝐭'𝐬 𝐭𝐢𝐦𝐞 𝐭𝐨 𝐛𝐮𝐢𝐥𝐝 𝐭𝐡𝐞 𝐜𝐚𝐩𝐢𝐭𝐚𝐥 𝐬𝐭𝐚𝐜𝐤 𝐟𝐨𝐫 𝐨𝐮𝐫 𝐥𝐢𝐟𝐞 𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐟𝐮𝐭𝐮𝐫𝐞. As part of the AusBiotech Invest 2025 program, this panel will dive into the critical topic of building Australia’s future life sciences capital stack and creating repeatable success stories. Be part of the discussion - https://lnkd.in/d9bgkzCP Australia produces world-class science, but our capital stack is uneven — strong at seed and translation, thin at Series A/B, and shallow at the growth end. Other global hubs like Israel, the UK, Switzerland, and Singapore once faced the same challenge but built strong capital markets to fund innovation. This panel brings together leading investors, corporates, and financiers to explore what Australia must build locally, what we should leverage globally, and how to ensure our companies scale at home while connecting to the global capital needed to catalyse health outcomes. Moderator: 📣 Kerri Lee Sinclair, Head of Investment, AusBiotech Panel: 📣 Medard Fischer, VP Strategic Investments Cochlear R&D, Cochlear 📣 Rowena Gracey, Director, ARCHIMED 📣 Sarah Meibusch, Partner, OneVentures 📣 Dr. Chris Nave, Founding Partner & Managing Director, Brandon Capital 📅 October 21, 2025 📍 Crown Towers Melbourne Discover our full program 👉 https://lnkd.in/gvwD3gJK #AusBiotechInvest2025 #ABI25 #LifeSciences #BiotechInvestment #CapitalStack #Innovation #HealthTech

Explore Groundbreaking Ophthalmology Solutions with PolyActiva at AusBiotech Invest 2025 Next Tuesday! PolyActiva Pty Ltd is a clinical-stage ophthalmology company on a mission to become a leader in sustained drug delivery for the eye, improving patient outcomes and quality of life. Their proprietary PREZIA™ platform delivers precise, controlled drug delivery using polymeric prodrug technology. Key developments: 🔹Lead candidate – PA5108: A biodegradable latanoprost ocular implant delivering 6 months of daily dosing for patients with open-angle glaucoma, eliminating the need for daily eye drops. 🔹Clinical progress: Currently in Phase 2b trials in the USA, with a registration study planned for early 2027. 🔹Pipeline potential: PREZIA™ technology is adaptable to multiple small drug molecules, opening opportunities to address additional back-of-eye indications. Speaker: 📣 Vanessa Waddell, Chief Strategy Officer, PolyActiva Pty Ltd Don’t miss the chance to hear how PolyActiva is redefining ophthalmic drug delivery with innovative, patient-friendly therapies. 📅 October 21, 2025 📍 Crown Towers Melbourne ⏰ The countdown is on — AusBiotech Invest is next Tuesday! Secure your spot now and connect with Australia’s leading biotech innovators 👉 https://lnkd.in/gnAvD4iQ #AusBiotechInvest2025 #ABI25 #PolyActiva #OphthalmologyInnovation #SustainedDrugDelivery #BiotechInvestment #LifeSciences #ClinicalResearch #DrugDevelopment

Meet the Innovators Advancing Oncology and Antiviral Therapies at AusBiotech Invest 2025 — 𝐋𝐞𝐬𝐬 𝐭𝐡𝐚𝐧 𝐚 𝐰𝐞𝐞𝐤 𝐭𝐨 𝐠𝐨 𝐛𝐞𝐟𝐨𝐫𝐞 𝐀𝐮𝐬𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐈𝐧𝐯𝐞𝐬𝐭 2025! MLS Bio (Molecular Life Science Biotech) is progressing a multi-asset pipeline designed to tackle some of the most urgent unmet needs in oncology and infectious disease. The company’s lead candidate, MLS-269, targets prostate cancer, with preclinical results showing potential to overcome resistance, improve tolerability, and expand treatment options for advanced and metastatic disease. Key developments: 🔹 Oncology focus: MLS-269 aims to redefine standards of care in prostate cancer 🔹Broad-spectrum antiviral: MLS-289 is in development for human and animal health applications, including Porcine Reproductive and Respiratory Syndrome (PRRS) 🔹Clinical progression: IND-enabling studies are underway, supported by collaborations with leading academic and clinical research institutions Speaker: 📣 Ms. Penelope Lane, CEO & Managing Director, MLS Bio (Molecular Life Science Biotech) Don’t miss the opportunity to hear how MLS Bio is translating breakthrough science into scalable therapies that address both cancer and global infectious disease challenges. 📅 October 21, 2025 📍 Crown Towers Melbourne Be part of the next wave of biotech innovation — secure your spot today 👉 https://lnkd.in/gnAvD4iQ #AusBiotechInvest2025 #ABI25 #MLSBio #OncologyInnovation #AntiviralTherapies #BiotechInvestment #LifeSciences #ClinicalResearch #DrugDevelopment